Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Liposomes in Total Neoadjuvant Therapy for Rectal Cancer
NCT07074353Phase 3Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jul 2025
- Primary completion
- Apr 2028
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of irinotecan liposome in rectal cancer, sponsored by Zhejiang Cancer Hospital. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
irinotecan liposome
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07074353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07074353.